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Dear Editor,
Eosinophilic annular erythema (EAE) is a rare figu-
rate dermatitis of unknown etiology with prominent 
tissue eosinophilia. 
A 59-year-old male patient presented with a one-
month history of itchy, polycyclic, annular, and par-
tially serpiginous lesions involving the back, the glu-
teal region, and the extremities (Figure 1, a, b). There 
was no medical history of drug intake. High potency 
local steroids and antihistamines were prescribed, 
but without adequate therapeutic results. Extensive 
laboratory work-up including serological infectious 
disease testing was performed and was within normal 
ranges. Histopathological examination of a biopsy 
taken from a lesion on the gluteus showed perivascu-
lar lymphocytic infiltrate around superficial and deep 
vascular plexus with admixture of eosinophils that 
was found interstitially (Figure 2, a,b) and within the 
lobules of subcutaneous fat. The overlying epidermis 
was unremarkable. There were no signs of flame fig-
ures and granulomatous inflammation. Based on the 
clinical and histopathological findings, a diagnosis of 
EAE was established. The patient was given 40 mg of 
prednisone orally which resulted in partial improve-
ment, but the lesions relapsed soon after the dose 
was tapered down to 20 mg. Chloroquine was started 
at a dose of 4 mg/kg daily for 10 days, then 250 mg 
daily for next the 10 weeks, resulting in complete 
clearance of all the lesions, which was sustained for 
over 2 years of follow-up.
It is still matter of debate whether EAE is a clini-
cal subtype of Wells syndrome (WS) presenting with 
an annular or figurate pattern or is a distinct entity. In 
recently published paper, El-Khalawany et al. argued 
that EAE is a peculiar clinical variant of WS, because 
flames figures, blood and tissue eosinophilia, and 
granulomatous infiltrate can be observed in well-de-
veloped and long-standing lesions (1). The etiology of 
EAE is still unknown, although it has been suggested 
that it occurs as a result of a hypersensitivity reaction 
to an unidentified allergen (2). EAE has been associ-
ated with Helicobacter pylori, Borrelia burgdorferi, and 
hepatitis C virus infection, diabetes mellitus, chronic 
Figure 1. (a) Polycyclic, annular and serpiginous lesions on the back and gluteal region. (b) Multiple annular erythematous 
lesions on the patient`s trunk.
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kidney disease, thymoma, autoimmune pancreatitis, 
autoimmune hypothyroidism, and internal malig-
nances (clear cell renal carcinoma, metastatic prostate 
adenocarcinoma) (3,4). Clinically, EAE is characterized 
by asymptomatic or mildly pruritic urticarial papules 
and plaques in annular configuration, mainly on the 
trunk and proximal extremities (5). Histologically, as in 
our patient, EAE is characterized by the appearance of 
a superficial and deep perivascular inflammatory infil-
trate composed of lymphocytes and abundant eosin-
ophils and absence of epidermal change (5). There is 
no standard treatment for EAE. Systemic steroids and 
antimalarials are the usual first-line options (5). Other 
treatment options include dapsone, indomethacin, cy-
closporine, and UVB therapy (1,3,5). Response to anti-
malarials is usually observed within the first 2-4 weeks 
(2). However, as in our case, it may take several weeks 
for patients to respond to antimalarial treatment, and 
complete regression may even take longer (3).
We believe that EAE should be treated with anti-
malarials over a longer time period in order to avoid 
frequent relapses. 
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Figure 2. (a) Unremarkable epidermis. Superficial, mid-
dermal dense infiltrate of lymphocytes around the vascu-
lar plexus. Extensive solar elastosis of the papillary dermis; 
hematoxylin and eosin ×10. (b) Perivascular infiltrate of 
lymphocytes with admixture of eosinophils also found in-
terstitially; hematoxylin and eosin ×40-
